發(fā)布時(shí)間：2018-09-06 12:24

【摘要】：目的探討美羅培南與烏司他丁在急診重癥感染患者治療中的應(yīng)用效果,為臨床治療提供參考依據(jù)。方法選取2013年6月-2015年6月于醫(yī)院接受治療的急診重癥感染住院患者100例為研究對(duì)象,根據(jù)隨機(jī)數(shù)字表法分成對(duì)照組和試驗(yàn)組,每組各50例,對(duì)照組采用美羅培南進(jìn)行,并采用呼吸輔助、營(yíng)養(yǎng)調(diào)節(jié)等措施;試驗(yàn)組在對(duì)照組的基礎(chǔ)上同時(shí)給予烏司他丁進(jìn)行治療,比較兩組患者臨床指標(biāo),數(shù)據(jù)采用SPPS 18.0軟件進(jìn)行統(tǒng)計(jì)分析。結(jié)果治療5d后,兩組患者血清前降鈣素原濃度、APACHEⅡ評(píng)分、腫瘤壞死因子-α(TNF-α)及高敏C-反應(yīng)蛋白(hs-CRP)濃度均降低,且試驗(yàn)組降低程度明顯大于對(duì)照組;對(duì)照組30d存活率明顯低于試驗(yàn)組(P0.05)。結(jié)論急診重癥感染患者在使用美羅培南抗感染、運(yùn)用呼吸輔助治療、營(yíng)養(yǎng)調(diào)節(jié)等有效措施的基礎(chǔ)上,加用烏司他丁治療,能有效改善其臨床體征,減輕感染對(duì)機(jī)體的損傷,達(dá)到理想的重癥感染治療效果。
[Abstract]:Objective to investigate the efficacy of meropenem and ulinastatin in the treatment of emergency patients with severe infection. Methods from June 2013 to June 2015, 100 patients with severe infection were randomly divided into two groups: control group (n = 50) and experimental group (n = 50). The control group was treated with meropenem. The experimental group was treated with ulinastatin on the basis of the control group, and the clinical indexes of the two groups were compared. The data were analyzed by SPPS 18.0 software. Results after 5 days of treatment, the serum procalcitonin concentration and Apache 鈪，

本文編號(hào)：2226342